Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis

Leukemia Research

Volumn 40, Issue , 2015, Pages 17-23

  Landfeldt, Erik ^a,b   Eriksson, Jennifer ^a   Ireland, Steve ^c   Musingarimi, Patience ^d   Jackson, Claire ^e   Tweats, Emma ^e   Gaudig, Maren ^f  

^a MAPI GROUP   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Janssen EMEA Business Intelligence   (United Kingdom)

^d Janssen Health Economics and Market Access EMEA   (United Kingdom)

^e ADELPHI REAL WORLD   (United Kingdom)

^f Janssen Health Economics and Market Access EMEA   (Germany)

Author keywords

Clinical practice; Decision making; Discrete choice experiment; Hematology; Leukemia

Indexed keywords

ARTICLE; BAYES THEOREM; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FATIGUE; FEMALE; GERMAN (CITIZEN); GERMANY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; SWEDEN; SWEDISH CITIZEN; TREATMENT OUTCOME; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY; RECURRENT DISEASE;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECURRENCE;

EID: 84949257140     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.11.006     Document Type: Article

References (26)

1. Zenz T., Mertens D., Kuppers R., et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 2010, 10(1):37-50.
2. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
3. Dores G.M., Anderson W.F., Curtis R.E., et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br. J. Haematol. 2007, 139(5):809-819.
4. Oscier D., Dearden C., Eren E., et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br. J. Haematol. 2012, 159(5):541-564.
5. Goede V., Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. Drugs Aging 2011, 28(3):163-176.
6. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013, 122(23):3723-3734.
7. Kutsch N., Hallek M., Eichhorst B. Emerging therapies for refractory chronic lymphocytic leukemia. Leuk. Lymphoma 2014, [Epub ahead of print].
8. National Comprehensive Cancer Network. NCCN guidelines: Non-Hodgkin's Lymphomas. Available from: (accessed 01.15.). http://www.nccn.org.
9. Shanafelt T.D., Bowen D.A., Venkat C., et al. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk. Res. 2009, 33(2):263-270.
10. Gaston C.M., Mitchell G. Information giving and decision-making in patients with advanced cancer: a systematic review. Soc. Sci. Med. 2005, 61(10):2252-2264.
11. Evans J., Ziebland S., Pettitt A.R. Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. Eur. J. Cancer Care (Engl.) 2012, 21(1):67-77.
12. Lindhiem O., Bennett C.B., Trentacosta C.J., McLear C. Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis. Clin. Psychol. Rev. 2014, 34(6):506-517.
13. Elkin E.B., Kim S.H., Casper E.S., et al. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. J. Clin. Oncol. 2007, 25(33):5275-5280.
14. Ryan M., Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000, 320:1530-1533.
15. Bridges J.F., Hauber A.B., Marshall D., et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force 706. Value Health 2011, 14:403-413.
16. Lloyd A., Penson D., Dewilde S., Kleinman L. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008, 11(2):153-159.
17. Hurvitz S.A., Lalla D., Crosby R.D., Mathias S.D. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res. Treat. 2013, 142(3):603-609.
18. Beusterien K., Grinspan J., Tencer T., et al. Patient preferences for chemotherapies used in breast cancer. Int. J. Womens Health 2012, 4:279-287.
19. Mühlbacher A.C., Nübling M. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur. J. Health Econ. 2011, 12(3):193-203.
20. Hershman D., Calhoun E., Zapert K., et al. Patients' perceptions of physician-patient discussions and adverse events with cancer therapy. Arch. Drug Inf. 2008, 1(2):70-78.
21. Mohamed A.F., Hauber A.B., Neary M.P. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics 2011, 29(11):977-988.
22. Bridges J.F., Mohamed A.F., Finnern H.W., et al. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer 2012, 77(1):224-231.
23. Shafey M., Lupichuk S.M., Do T., et al. Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant. 2011, 46(7):962-969.
24. McQuellon R.P., Muss H.B., Hoffman S.L., et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J. Clin. Oncol. 1995, 13(4):858-868.
25. Park M.H., Jo C., Bae E.Y., Lee E.K. A comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea. Value Health 2012, 15(6):933-939.
26. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (29-7-2014) Wahlbasierte Conjoint-Analyse-Pilotprojekt zur Identifikation, Gewichtung und Priorisierung multipler Attribute in der Indikation Hepatitis C. 29-7-2014.